Vectura Inks $622M Deal For Fellow UK Inhaler Maker
Vectura Group plc will snap up fellow U.K.-based inhaler developer Skyepharma PLC in a £441.3 million ($622 million) stock transaction, paving the way for the combined biotech to gain access to...To view the full article, register now.
Already a subscriber? Click here to view full article